104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

Assessment of Safety and Efficacy of BG9924 in Subjects With RA Who Have Participated in Study 104RA202.

To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.

Inclusion Criteria:

• Must be a participant from Study 104RA202 (NCT 00664716)
• Stable dose of Methotrexate for the duration of the study

Exclusion Criteria:

• Participants with a significant change in their medical history from their previous BG9924 study
• Any clinically significant infectious illness or serious local infection

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.